ArticleBMC cancer2025
Anatomical-biochemical discordance and prognostic role of bone metastases in advanced MTC treated with [¹⁷⁷Lu]Lu-DOTA-TATE.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedullary thyroid carcinoma (MTC) is a rare malignancy with limited treatment options in the metastatic setting. While peptide receptor radionuclide therapy (PRRT) with [¹⁷⁷Lu]Lu-DOTA-TATE has been well established in gastroenteropancreatic neuroendocrine tumors, its clinical utility in MTC remains under investigation.
methodsWe retrospectively analyzed 18 patients with advanced, somatostatin receptor-positive MTC treated with [¹⁷⁷Lu]Lu-DOTA-TATE. Treatment decisions-including in patients with low somatostatin receptor (SSTR) expression or first-line PRRT indication-were made by a multidisciplinary tumor board. Anatomical response was assessed using RECIST 1.1 on [⁶⁸Ga]Ga-DOTA-TATE PET/CT after two cycles. Biochemical and clinical outcomes were also recorded. Progression-free survival (PFS) was evaluated using Kaplan-Meier and Cox regression.
resultsMedian PFS was 37.0 months. Radiologic disease control -defined as partial response (PR) or stable disease (SD) -was achieved in 78%, and biochemical response (≥ 50% decrease in calcitonin) in 44% of patients. Patients with bone metastases had significantly shorter PFS (24.6 vs. 47.0 months, p = 0.027). Longer PFS was also observed in those receiving higher cumulative dose, those with larger solitary tumors, and those treated in the first-line setting, although these trends did not reach statistical significance. Discordance between anatomical and biochemical response was observed in 50% of cases, highlighting limitations of calcitonin-based monitoring.
conclusionPRRT with [¹⁷⁷Lu]Lu-DOTA-TATE is a well-tolerated treatment option for selected patients with advanced MTC, including those receiving first-line therapy and those with low SSTR expression. In our limited cohort, bone metastases were associated with shorter PFS, and discordant imaging/biochemical responses are common. Functional imaging-guided selection and individualized response assessment are essential for optimal management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.